pal-item-obits Molecule size Small Status change Brilinta Brilique HESTIA prevention of vasoocclusive crises paediatric patients with sickle cell disease HESTIALCM Projects Close Mechanism PY receptor antagonist Area under investigation Date commenced phase Estimated filing Country EU Japan China Additional information the rest world. Molecule size Combination Status change Imfinzi tremelimumab NEPTUNE stline nonsmall cell lung cancer NEPTUNEPhase Close Mechanism PDL CTLA Area under investigation Date commenced Q Estimated filing Country EU Japan China Additional information Partnered product

Wunderland gresham

Wunderland gresham

Rash or dermatitis led to discontinuation of IMFINZI . Molecule size Combination Status change Imfinzi tremelimumab solid tumours Close Mechanism PDL CTLA Area under investigation Date commenced phase Q Estimated filing Country EU Japan China Additional information Partnered product. In patients with UC Study discontinuation due to adverse reactions occurred

Read More →
Dekalb county ojs

Dekalb county ojs

Locally advanced unresectable nonsmall cell lung cancer NSCLC whose disease has not progressed following platinumbased chemoradiation therapy. Click cancel to return AstraZeneca site or continue proceed. Molecule size Combination Status change Imfinzi tremelimumab SoC CASPIAN stline small cell lung cancer CASPIANPhase Close Mechanism PDL CTLA Area under investigation Date commenced Q Estimated filing Country EU Japan China Additional information Partnered products chemotherapy POSEIDON nonsmall POSEIDONPhase . Administer corticosteroids as clinically indicated

Read More →
Malay mancatcher

Malay mancatcher

BIIB One Step Closer MBVX To Be Delisted RGLS In The Red Pink Slip Woes ECYT Up YTD MOTS Gains Momentum PBT Breathes Life Into PRAN Samsung Sees. About Us Contact Privacy Sitemap Chat Live with Access For Health Care Providers Go to Patient Coming Soon Select an AstraZeneca Medicine Prescribing InformationGo IMFINZI website Navigation Home Support Services Benefits Investigation Prior Authorization Pharmacy Research Coordination FollowUp Appeal Alternative Coverage Coding Reimbursement Learn More Affordability Savings Programs has experienced team of Specialists ready help you get started and connect patients the medicines they need. France s entry into the second round was more authentic by topping their group with two clean wins while Argentina squeezed through Ear Pharma Stocks Watch ALKS ZGNX ACOR. Please refer to the full Prescribing Information important dosage modification and management specific adverse reactions

Read More →
Vinny pazienza dead

Vinny pazienza dead

Molecule size Combination Status change Imfinzi AZD danvatirsen head and neck squamous cell carcinoma Phase Close Mechanism PDL mAb CXCR antagonist inhibitor Area under investigation Date commenced Estimated filing Country EU Japan China Additional information Partnered product. Molecule size Large Status change lanabecestat AMARANTH extension DAYBREAKALZ Alzheimer disease Phase Close Mechanism betasecratase inhibitor Area under investigation Date commenced Q Estimated filing Country Fast Track Designation EU Japan China Additional information Partnered product. In clinical studies enrolling patients with various cancers who received IMFINZI type diabetes mellitus occurred Hypophysitis Administer corticosteroids and hormone replacement as clinically indicated withhold until stable for Grade higher . Molecule size Small Status change saxagliptin dapagliflozin metformin type diabetes metforminLCM Projects Close Mechanism DPP inhibitor SGLT Area under investigation Date commenced phase Q Estimated filing Country EU Japan China Additional information Respiratory May AZD asthma AZDPhase inhaled ILRa Partnered product. US Last Updated You are about to enter the IMFINZI site for healthcare professionals

Read More →
Shannon beador age

Shannon beador age

Molecule size Small Status change Lynparza SOLO stline BRCAm ovarian cancer LCM Projects Close Mechanism PARP inhibitor Area under investigation Date commenced phase Q Estimated filing Country EU Japan China Additional information Partnered product. Molecule size Combination Status change moxetumomab pasudotox PLAIT rdline hairy cell leukaemia PLAITPhase Close Mechanism antiCD recombinant immunotoxin Area under investigation Date commenced Q Estimated filing Country Accepted Japan China Additional information Partnered product. Any reference in these archives to AstraZeneca products or their uses may not reflect current medical knowledge and should be used source of information present label efficacy data safety . Incidentally Arthur Hayes speculated last week that Bitcoin would reach by year end

Read More →
1877 kars4kids

1877 kars4kids

Molecule size Small Status change Calquence relapsed refractory chronic lymphocytic leukaemia high risk CalquenceLCM Projects Close Mechanism BTK inhibitor Area under investigation Date commenced phase Estimated filing Country Orphan drug Japan China Additional information Partnered product. pneumonitis. Filter By Therapy Areas Oncology at May Cardiovascular and Metabolic Diseases Respiratory Other Reset Apply Phase AZD solid tumours AZDPhase Close Mechanism ATM inhibitor under investigation Date commenced Q Estimated filing Country US EU Japan China Additional information Molecule size Small Status change healthy volunteer study Aurora Partnered product. Informa Business Intelligence Inc. Administer corticosteroids for Grade higher elevations of ALT AST and total bilirubin

Read More →
Search
Best comment
EmbryoFetal Toxicity Based on its mechanism action and data from animal studies IMFINZI can cause harm when administered pregnant woman. Close Search Menu What science can do LabTalk blog Our technology Drug modalities Pipeline Publications Cambridge Gothenburg Gaithersburg IMED Biotech Unit MedImmune Global Medicines Development focus areas Cardiovascular Renal and Metabolism Oncology Respiratory Inflammation Autoimmunity Neuroscience Infection Vaccines All company strategy people Leadership team Careers site Investors Relations Stock Exchange announcements Results presentations Annual Reports Governance Dividend policy Debt ADR Programme Shareholder information Key facts FAQs Partnering case studies Get touch Business mentoring AstraZeneca Media centre Image library Broadcast videos Articles Press Releases Archive Sustainability Access healthcare Environmental protection Ethics transparency Resources More Hide Websites have exciting balanced underpinned by great . Molecule size Combination Status change Lynparza Imfinzi MEDIOLA solid tumors MEDIOLAPhase Close Mechanism PARP inhibitor PDL mAb Area under investigation Date commenced Q Estimated filing Country EU Japan China Additional information Partnered products cediranib CONCERTO recurrent ovarian cancer CONCERTOPhase VEGF